InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.800 0.005 (0.63%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$382 Successful completion of VivaGel study sexually active women 12 Mar 2010 11:11AM $0.715 $0.800 risen by 11.89%
$382 Half Yearly Report and Accounts 18 Feb 2010 11:21AM $0.700 $0.800 risen by 14.29%
$382 Starpharma and Lilly Sign New Drug Delivery Collaboration 1 Feb 2010 9:44AM $0.720 $0.800 risen by 11.11%
$382 Appendix 4C - quarterly 29 Jan 2010 10:19AM $0.720 $0.800 risen by 11.11%
$382 Reinstatement to Official Quotation 18 Nov 2009 10:00AM $0.600 $0.800 risen by 33.33%
$382 Starpharma announces $15.6 million capital raising 18 Nov 2009 10:00AM $0.600 $0.800 risen by 33.33%
$382 Suspension from Official Quotation 16 Nov 2009 9:36AM $0.600 $0.800 risen by 33.33%
$382 Trading Halt 12 Nov 2009 9:18AM $0.600 $0.800 risen by 33.33%
$382 Starpharma signs agrochemicals deal 5 Nov 2009 10:59AM $0.585 $0.800 risen by 36.75%
$382 Appendix 4C - quarterly 23 Oct 2009 10:33AM $0.545 $0.800 risen by 46.79%
$382 US Patent Grant Extends VivaGel Coverage to 2024 22 Sep 2009 1:29PM $0.470 $0.800 risen by 70.21%
$382 Preliminary Final Report 24 Aug 2009 3:27PM $0.470 $0.800 risen by 70.21%
$382 Interim Financial Results - Material Improvement 4 Aug 2009 11:39AM $0.420 $0.800 risen by 90.48%
$382 VivaGel - Anti-HIV and Herpes Activity following human admin 3 Aug 2009 1:06PM $0.450 $0.800 risen by 77.78%
$382 Appendix 4C - quarterly 27 Jul 2009 1:45PM $0.330 $0.800 risen by 142.42%
$382 Completes $7.1m capital raising 21 May 2009 6:42PM $0.320 $0.800 risen by 150%
$382 Elanco deal triggers Starpharma SPP extension 11 May 2009 10:18AM $0.300 $0.800 risen by 166.67%
$382 Starpharma and Elanco sign agreement 11 May 2009 8:41AM $0.300 $0.800 risen by 166.67%
$382 Appendix 4C - quarterly 7 Apr 2009 9:15AM $0.270 $0.800 risen by 196.30%
$382 Raises additional capital via institutional placement 7 Apr 2009 9:14AM $0.270 $0.800 risen by 196.30%
$382 Trading Halt 3 Apr 2009 10:14AM $0.300 $0.800 risen by 166.67%
$382 Completes patient testing in retention of activity study 19 Mar 2009 12:24PM $0.190 $0.800 risen by 321.05%
$382 Half Yearly Report and Accounts 19 Feb 2009 4:55PM $0.170 $0.800 risen by 370.59%
$382 Topical Microbicide Field Boost With Efficacy Result 10 Feb 2009 1:10PM $0.200 $0.800 risen by 300%
$382 Appendix 4C - quarterly 30 Jan 2009 12:03PM $0.180 $0.800 risen by 344.44%

776 - 800 of 890 results

Page 32 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.